CoChat

ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer

Open access
Ye, Q, Cai, W, Zheng, Y, Evers, B M, She, Q-B · 2014 · Oncogene
Cited by 163

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

The mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase (MEK/ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways are often concurrently activated by separate genetic alterations in colorectal cancer (CRC), which is associated with CRC progression and poor survival. However, how activating both pathways is required for CRC metastatic progression remains unclear. Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation. Here, we identified that the activation of cap-dependent translation by cooperative ERK and AKT signaling is critical for promotion of CRC motility and metastasis. In CRC cells with coexistent mutational activation of ERK and AKT pathways, inhibition of either MEK or AKT alone showed limited activity in inhibiting cell migration and invasion, but combined inhibition resulted in profound effects. Genetic blockade of the translation initiation complex by eIF4E knockdown or expression of a dominant active 4E-BP1 mutant effectively inhibited migration, invasion and metastasis of CRC cells, whereas overexpression of eIF4E or knockdown of 4E-BP1 had the opposite effect and markedly reduced their dependence on ERK and AKT signaling for cell motility. Mechanistically, we found that these effects were largely dependent on the increase in mammalian target of rapamycin complex 1 (mTORC1)-mediated survivin translation by ERK and AKT signaling. Despite the modest effect of survivin knockdown on tumor growth, reduction of the translationally regulated survivin profoundly inhibited motility and metastasis of CRC. These findings reveal a critical mechanism underlying the translational regulation of CRC metastatic progression, and suggest that targeting cap-dependent translation may provide a promising treatment strategy for advanced CRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2013.122

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 35

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. · DOI · Paper page
  2. Chu E . An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer 2012; 11: 1–13. · DOI
  3. Sebolt-Leopold JS, Herrera R . Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937–947. · DOI · Paper page
  4. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005; 436: 792. · DOI · Paper page
  5. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ . Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009; 125: 2332–2341. · DOI · Paper page
  6. Sonenberg N, Hinnebusch AG . Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731–745. · DOI · Paper page
  7. Mamane Y, Petroulakis E, Martineau Y, Sato TA, Larsson O, Rajasekhar VK et al. Epigenetic activation of a subset of mRNAs by eIF4E explains its effects on cell proliferation. PLoS One 2007; 2: e242. · DOI · Paper page
  8. Livingstone M, Atas E, Meller A, Sonenberg N . Mechanisms governing the control of mRNA translation. Phys Biol 2010; 7: 021001. · DOI · Paper page
  9. Silvera D, Formenti SC, Schneider RJ . Translational control in cancer. Nat Rev Cancer 2010; 10: 254–266. · DOI · Paper page
  10. Rosenwald IB, Chen JJ, Wang S, Savas L, London IM, Pullman J . Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999; 18: 2507–2517. · DOI · Paper page
  11. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A . Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 2001; 10: 663–666.
  12. Martin ME, Perez MI, Redondo C, Alvarez MI, Salinas M, Fando JL . 4E binding protein 1 expression is inversely correlated to the progression of gastrointestinal cancers. Int J Biochem Cell Biol 2000; 32: 633–642. · doi:10.1016/s1357-2725(00)00007-8
  13. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B et al. 4E-binding protein 1: a key molecular ‘funnel factor’ in human cancer with clinical implications. Cancer Res 2007; 67: 7551–7555. · DOI · Paper page
  14. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K et al. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 2011; 29: 4688–4695. · DOI · Paper page
  15. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov 2012; 2: 56–67. · DOI · Paper page
  16. Altieri DC . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61–70. · DOI · Paper page
  17. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC . IAP regulation of metastasis. Cancer Cell 2010; 17: 53–64. · DOI · Paper page
  18. McKenzie JA, Liu T, Goodson AG, Grossman D . Survivin enhances motility of melanoma cells by supporting Akt activation and alpha 5 integrin upregulation. Cancer Res 2010; 70: 7927–7937. · DOI
  19. Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY et al. Survivin is a potential mediator of prostate cancer metastasis. Int J Radiat Oncol Biol Phys 2010; 78: 1095–1103. · DOI
  20. Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y et al. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2012; 105: 520–528. · doi:10.1002/jso.22134
  21. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D et al. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7: e38. · DOI · Paper page
  22. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110: 163–175. · DOI · Paper page
  23. Dilling MB, Germain GS, Dudkin L, Jayaraman AL, Zhang X, Harwood FC et al. 4E-binding proteins, the suppressors of eukaryotic initiation factor 4E, are down-regulated in cells with acquired or intrinsic resistance to rapamycin. J Biol Chem 2002; 277: 13907–13917. · DOI · Paper page
  24. Ilic N, Utermark T, Widlund HR, Roberts TM . PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci USA 2011; 108: E699–E708. · DOI · Paper page
  25. Zindy P, Berge Y, Allal B, Filleron T, Pierredon S, Cammas A et al. Formation of the eIF4F translation–initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptors. Cancer Res 2011; 71: 4068–4073. · DOI · Paper page
  26. Nguyen DX, Massague J . Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8: 341–352. · DOI · Paper page
  27. Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer 2011; 10: 188–193. · DOI
  28. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71: 3246–3256. · DOI · Paper page
  29. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052–7058. · DOI · Paper page
  30. Mazzoletti M, Bortolin F, Brunelli L, Pastorelli R, Di Giandomenico S, Erba E et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res 2011; 71: 4573–4584. · DOI
  31. Thomas HE, Mercer CA, Carnevalli LS, Park J, Andersen JB, Conner EA et al. mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma. Sci Transl Med 2012; 4: 139ra184. · DOI
  32. Floc'h N, Kinkade CW, Kobayashi T, Aytes A, Lefebvre C, Mitrofanova A et al. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. Cancer Res 2012; 72: 4483–4493. · DOI
  33. Moroz E, Carlin S, Dyomina K, Burke S, Thaler HT, Blasberg R et al. Real-time imaging of HIF-1alpha stabilization and degradation. PLoS One 2009; 4: e5077. · DOI · Paper page
  34. Pause A, Belsham GJ, Gingras AC, Donze O, Lin TA, Lawrence JC et al. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 1994; 371: 762–767. · DOI · Paper page
  35. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008; 3: e3065. · DOI · Paper page

Cited by

See all 163

Metadata

Authors
Ye, Q., Cai, W., Zheng, Y., Evers, B. M., & She, Q.-B.
Venue
Oncogene
Published
2013-04-29
Volume
33
Issue
14
Pages
1828-1839
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2057507337
Cited by
163
References
16
FWCI
8.34
Type
journal article
Language
en
Open access
green
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.